Personas / Equipo Humano

Susana Rives Solà

Buscador de publicaciones

Publicaciones

  • Ghorashian S, Jacoby E, De Moerloose B, Rives-Solà S, Bonney D, Shenton G, Bader P, Bodmer N, Quintana AM, Herrero B, Algeri M, Locatelli F, Vettenranta K, Gonzalez B, Attarbaschi A, Harris S, Bourquin JP and Baruchel A.

    Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.

    The Lancet. Haematology . 9(10): 766-775. Nº de citas: 7

    [doi:10.1016/S2352-3026(22)00225-3]

  • Bueno C, Barrena S, Bataller A, Ortiz-Maldonado V, Elliott N, O'Byrne S, Wang G, Rovira M, Gutierrez-Agüera F, Trincado JL, Gonzalez M, Morgades M, Sorigué M, Barcena P, Zanetti SR, Torrebadell-Burriel M, Vega-García N, Rives-Solà S, Mallo M, Sole F, Mead AJ, Roberts I, Thongjuea S, Psaila B, Juan-Otero M, Delgado J, Urbano-Ispizua Á, Ribera JM, Orfao A, Roy A and Menéndez P.

    CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

    Blood . 140(1): 38-44. Nº de citas: 14

    [doi:10.1182/blood.2021014840]

  • Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives-Solà S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F and Zwaan CM.

    Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.

    Leukemia . 36(6): 1516-1524. Nº de citas: 17

    [doi:10.1038/s41375-022-01576-3]

  • Laetsch TW, Maude SL, Balduzzi A, Rives-Solà S, Bittencourt H, Boyer MW, Buechner J, De Moerloose B, Qayed M, Phillips CL, Pulsipher MA, Hiramatsu H, Tiwari R and Grupp SA.

    Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.

    Leukemia . 36(6): 1508-1515. Nº de citas: 14

    [doi:10.1038/s41375-022-01550-z]

  • Ortiz-Maldonado V, Alonso-Saladrigues A, Español-Rego M, Martínez-Cibrián N, Faura A, Magnano L, Català-Temprano A, Benítez-Ribas D, Giné E, Díaz-Beyá M, Correa JG, Rovira M, Montoro-Lorite M, Martínez-Roca A, Rodríguez-Lobato LG, Cabezón R, Cid J, Lozano M, Garcia-Rey E, Conde N, Pedrals G, Rozman M, Torrebadell-Burriel M, Setoain X, Rodríguez S, Esteve J, Pascal M, Urbano-Ispizua Á, Juan-Otero M, Delgado J and Rives-Solà S.

    Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease

    AMERICAN JOURNAL OF HEMATOLOGY . 97(6): 731-739. Nº de citas: 2

    [doi:10.1002/ajh.26519]

  • Vicente-Garces C, Esperanza-Cebollada E, Montesdeoca S, Torrebadell-Burriel M, Rives-Solà S, Dapena JL, Català-Temprano A, Conde N, Camós-Guijosa M and Vega-García N.

    Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia

    Frontiers in Molecular Biosciences . 9: 854098-854098. Nº de citas: 4

    [doi:10.3389/fmolb.2022.854098]

  • Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz MJ, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui CH, Rives-Solà S, Schmiegelow K, Silverman LB, Stary J, Vora A and Brown PA.

    Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.

    Blood . 139(12): 1785-1793. Nº de citas: 16

    [doi:10.1182/blood.2021012328]

  • Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Dapena JL, Rives-Solà S, Sevilla J, Menárguez López Á, Panesso Romero M, Montoya C, Vagace JM, Molina Hurtado JR, García-Morín M, García Abós M, Mendoza Sánchez MC, Lendínez F, Palomo Moraleda P, Tallón M, González B, Urrutia E, Serna JV, Peláez Pleguezuelos I, Martínez Merino M, Ramos Elbal E, Orellana E, Benítez Muñoz H and Berrueco R.

    Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS . 20(6): 1390-1399. Nº de citas: 5

    [doi:10.1111/jth.15699]

  • Buechner J, Caruana I, Künkele A, Rives-Solà S, Vettenranta K, Bader P, Peters C, Baruchel A and Calkoen FG.

    Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?

    Frontiers in pediatrics . 9: 784024-784024. Nº de citas: 8

    [doi:10.3389/fped.2021.784024]

  • Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives-Solà S, Boyer MW, Hiramatsu H, Yanik GA, Driscoll T, Myers GD, Bader P, Baruchel A, Buechner J, Stefanski HE, Kalfoglou C, Nguyen K, Waldron ER, Thudium Mueller K, Maier HJ, Kari G and Grupp SA.

    Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

    blood cancer discovery . 3(1): 66-81. Nº de citas: 66

    [doi:10.1158/2643-3230.BCD-21-0095]